N/A N=23 A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections
Systemic Fungal Infections
Primary: Diagnosis of Systemic Fungal Infection (SFI) — 20; 6; 18; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Phase 2 N=203 Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
Invasive Fungal Infections
Primary: Data Review Committee (DRC) Adjudicated Overall Response at Day 42 — 28.7 Response rate percentage
Phase 4 N=45 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
N/A N=130 Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)
Mycoses · Leukemia
Primary: Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution — 32.3 Percentage of participants
Phase 4 N=13 Antifungal Locks to Treat Fungal-related Central Line Infections
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…
Phase 2 N=168 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal Meningitis · HIV Infections
Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012
N/A N=323 Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
Febrile Neutropenia
Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…
Phase 3 N=149 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Aspergillosis · Invasive Fungal Infections
Primary: Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT). — 25.0; 50.0; 14.3; 9.1…
Phase 3 N=204 A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Invasive Candidiasis
Primary: Number of Patients Who Develop Significant Drug-related Adverse Events. — 2; 3 Participants
Phase 3 N=216 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Phase 3 N=62 Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
Fungal Infection
Primary: Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment — 6; 32; 11; 10 Participants
Phase 2 N=112 Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Invasive Fungal Infection — 3; 4; 2 participants
Phase 4 N=222 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Invasive Candidiasis
Primary: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. — 9.8…
Phase 2 N=143 Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
Cryptococcal Meningitis
Primary: Number of Grade 3-5 Adverse Experiences That Are Definitely or Probably Related to Study Drug — 2; 1; 0; 0 Events
N/A N=177 Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection
Invasive Fungal Infections
Primary: Number of Participants With Clinical and/or Mycological Efficacy by Response at the End of Treatment (EOT) Visit — 64; 64; 36; 34 participants
Phase 4 N=71 An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections
Pulmonary Fungal Infection
Primary: Number of Participants With Clinical Efficacy — 8; 29; 18; 5 participants
Phase 2 N=219 Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
Cryptococcal Meningitis
Primary: Early Fungicidal Activity — 0.39; 0.28 log10 CFU/mL/day
Phase 3 N=88 Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
Invasive Fungal Infections
Primary: Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole Levels at Day 14 — 60.5; 71.0 percentage of participants
N/A N=808 A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation
Invasive Fungal Infections
Primary: The Rate of Invasive Fungal Infections — 77; 27 participants — p=0.007
Phase 2 N=20 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Mucormycosis
Primary: Safety and Tolerability of Adjunctive Deferasirox Therapy in Patients Being Treated With LAmB for Mucormycosis
N/A N=116 An Observational Study of Fungal Biomarkers (MK-0000-089)
Aspergillosis
Primary: Average of the Z-scores of the Time-Weighted Averages (TWA) of Fungal Biomarkers Galactomannan (GM) and (1,3)-β-D-glucan (βDG) Over the First Two Weeks of Treatment for…
Phase 3 N=233 Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Invasive Candidiasis · Mucocutaneous Candidiasis · Coccidioidomycosis
Primary: Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease. — 142; 69; 22; 131 Participants
Phase 4 N=113 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Time to Failure — 16; 13 Days
Phase 3 N=252 Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)
Leukopenia
Primary: Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period — 4; 11 participants
Phase 3 N=517 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI) — 3.1; 7.2 Percentage of participants
Phase 1 N=279 Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)
Fungal Infection
Primary: Single Dose Trough Concentration of IV Posaconazole (Cmin) — 318; 295; 467 ng/mL
Phase 2 N=65 Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
N/A N=249 Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
COVID-19 Respiratory Infection · Aspergillosis
Primary: Incidence of COVID-19 Associated Pulmonary Aspergillosis (CAPA) — 1.69; 0.84; 7.18 Cases per 1000 ICU days
N/A N=64 β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
Invasive Candidiasis
Primary: Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients. — 3; 3; 19; 9 participants